Education
About Us
Working with TipRanks
Follow Us
MicroPort NeuroTech Limited (HK:2172)
:2172
2172 Stock Chart & Stats
HK$11.30
HK$0.09(1.14%)
At close: 4:00 PM EST
HK$11.30
HK$0.09(1.14%)
Day’s Range― - ―
52-Week RangeHK$9.02 - HK$19.06
Previous CloseN/A
Volume491.15K
Average Volume (3M)2.57M
Market Cap
HK$6.97B
Enterprise ValueHK$5.52B
Total Cash (Recent Filing)HK$1.01B
Total Debt (Recent Filing)HK$24.72M
Price to Earnings (P/E)31.5
Beta0.89
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.5%
Share Statistics
EPS (TTM)0.17
Shares Outstanding585,034,800
10 Day Avg. Volume2,683,063
30 Day Avg. Volume2,571,422
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.74
Price to Sales (P/S)6.15
P/FCF Ratio16.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.58
Revenue Forecast (FY)HK$6.45B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelA business model that mixes initial device sales with recurring consumables and maintenance creates durable revenue streams and higher customer lifetime value. Recurring revenue smooths cash flow, supports predictable install-base monetization and underpins long‑term margin resilience.
Strong Margins And ProfitabilitySustained strong gross and net margins indicate effective pricing and cost control in medically differentiated products. Healthy EBIT/EBITDA margins support reinvestment in R&D and commercialization, enabling durable profitability as the company scales its neurostimulation platforms.
Low Leverage And High ROEA low-leverage balance sheet with strong ROE provides financial resilience and flexibility to fund product development or selective M&A without heavy interest burden. Efficient equity use suggests management converts capital into returns, supporting sustainable long‑term growth.
Bears Say
Weak Operating Cash FlowZero reported operating cash flow in the most recent period signals potential cash generation issues despite accounting profits. Poor OCF can limit the firm’s ability to self‑fund R&D, service working capital needs, or support consistent dividends and may require external financing.
Recent Revenue And EPS DeclinesNegative trailing revenue and EPS growth indicate near‑term top‑line pressure or margin headwinds that could persist. Continued declines hinder scale economics, reduce internal cash generation and may force tougher choices on pricing, investment pacing, or margin preservation strategies.
High Equity Reliance Limits Leverage BenefitsA capital structure skewed toward equity reduces financial leverage benefits such as amplified returns and tax shields. This conservatism can constrain capital efficiency for large expansions or acquisitions, potentially slowing growth relative to peers that optimize leverage.
MicroPort NeuroTech Limited News
2172 FAQ
What was MicroPort NeuroTech Limited’s price range in the past 12 months?
MicroPort NeuroTech Limited lowest stock price was HK$9.02 and its highest was HK$19.06 in the past 12 months.
What is MicroPort NeuroTech Limited’s market cap?
MicroPort NeuroTech Limited’s market cap is HK$6.97B.
When is MicroPort NeuroTech Limited’s upcoming earnings report date?
MicroPort NeuroTech Limited’s upcoming earnings report date is Apr 01, 2026 which is in 39 days.
How were MicroPort NeuroTech Limited’s earnings last quarter?
MicroPort NeuroTech Limited released its earnings results on Aug 27, 2025. The company reported HK$0.175 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.175.
Is MicroPort NeuroTech Limited overvalued?
According to Wall Street analysts MicroPort NeuroTech Limited’s price is currently Overvalued.
Does MicroPort NeuroTech Limited pay dividends?
MicroPort NeuroTech Limited pays a Quarterly dividend of HK$0.05 which represents an annual dividend yield of 1.5%. See more information on MicroPort NeuroTech Limited dividends here
What is MicroPort NeuroTech Limited’s EPS estimate?
MicroPort NeuroTech Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MicroPort NeuroTech Limited have?
MicroPort NeuroTech Limited has 585,034,800 shares outstanding.
What happened to MicroPort NeuroTech Limited’s price movement after its last earnings report?
MicroPort NeuroTech Limited reported an EPS of HK$0.175 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.387%.
Which hedge fund is a major shareholder of MicroPort NeuroTech Limited?
Currently, no hedge funds are holding shares in HK:2172
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroPort NeuroTech Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.98%
12-Months-Change
Fundamentals
Return on Equity
11.79%
Trailing 12-Months
Asset Growth
1.82%
Trailing 12-Months
Company Description
MicroPort NeuroTech Limited
MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. The company also provides APOLLO, an intracranial arterial stent system to treat intracranial atherosclerotic disease; and Bridge, a rapamycin target eluting vertebral artery stent system to treat cerebral atherosclerotic stenosis. In addition, it offers Neurohawk, a stent thrombectomy device; Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
―
LifeTech Scientific Corporation
―
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
―
MicroPort CardioFlow Medtech Corp.
―
Options Prices
Currently, No data available
---